From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
От сердечно-сосудисто-почечно-метаболического синдрома к сердечно-сосудисто-почечно-печёночно-метаболическому синдрому: предложение расширенной концептуальной модели
2025-02-02
SCID: 54.1/x2qascvq
Discuss with AI
Cardiometabolic diseasesCardiovascular-Kidney-Metabolic syndromeCardiovascular-Renal-Hepatic-Metabolic syndromeInter-organ dynamicsMetabolic dysfunction-associated steatotic liver disease
Figures from the paper
Abstract (AI)
Cardiometabolic diseases represent an escalating global health crisis, slowing or even reversing earlier declines in cardiovascular disease (CVD) mortality. Traditionally, conditions such as obesity, type 2 diabetes mellitus (T2DM), atherosclerotic CVD, heart failure (HF), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease (MASLD) were managed in isolation. However, emerging evidence reveals that these disorders share overlapping pathophysiological mechanisms and treatment strategies. In 2023, the American Heart Association proposed the Cardiovascular-Kidney-Metabolic (CKM) syndrome, recognizing the interconnected roles of the heart, kidneys, and metabolic system. Yet, this model omits the liver-a critical organ impacted by metabolic dysfunction. MASLD, which can progress to metabolic dysfunction-associated steatohepatitis (MASH), is closely tied to insulin resistance and obesity, contributing directly to cardiovascular and renal impairment. Notably, MASLD is bidirectionally associated with the development and progression of CKM syndrome. As a result, we introduce an expanded framework-the Cardiovascular-Renal-Hepatic-Metabolic (CRHM) syndrome-to more comprehensively capture the broader inter-organ dynamics. We provide guidance for an integrated diagnostic approach aimed at halting progression to advanced stages and preventing further organ damage. In addition, we highlight advances in medical management that target shared pathophysiological pathways, offering benefits across multiple organ systems. Viewing these conditions as an integrated whole, rather than as discrete entities, and incorporating the liver into this framework fosters a more holistic management strategy and offers a promising path to addressing the cardiometabolic pandemic.
Key Findings
1
An integrated diagnostic approach is recommended to halt progression to advanced disease stages and prevent further organ damage.
2
MASLD has bidirectional associations with the development and progression of Cardiovascular-Kidney-Metabolic syndrome.
3
MASLD is closely linked to insulin resistance and obesity and can progress to MASH, contributing directly to cardiovascular and renal impairment.
4
Targeting shared pathophysiological pathways may provide therapeutic benefits across multiple organ systems and support holistic cardiometabolic management.
5
The proposed Cardiovascular-Renal-Hepatic-Metabolic (CRHM) syndrome expands the 2023 AHA Cardiovascular-Kidney-Metabolic framework by incorporating the liver.
Research Object
Cardiovascular-Renal-Hepatic-Metabolic (CRHM) syndrome and its interconnected heart, kidney, liver, and metabolic disorders
Research Subject
The inter-organ pathophysiological relationships, progression, diagnosis, and integrated management of CRHM syndrome
Publication Details
Publication Date
2025-02-02
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest